# 58 Year-old Male with Alcoholic Cirrhosis Presents with Hyponatremia

# MEDICINE

Jess Hwang 11/8/12

#### **HPI**

- Fluid leaking from umbilical hernia secondary to his ascites
- Went to OR for drain placement which was complicated by hepatorenal syndrome
- Kidney function improved after 10 days and he was discharged home with followup with transplant clinic for eval for liver transplant

#### 2 weeks later

- Admitted from clinic for acute on chronic kidney injury
- He has had a history of hyponatremia with Na ranging from 128-132
- Morning of discharge, underwent cosyntropin stim which was abnormal, endocrinology consulted

# **Symptoms**

- No orthostasis, weakness,
- No anorexia, lethargy
- No nausea or vomiting
- No hyperpigmentation, salt craving
- No palpitations, no pre-syncope
- No AMS per family
- Occasional shortness of breath depending on his ascites. Feels much better after paracentesis.

PMH
Alcoholic cirrhosis
CKD (GFR 40-50)

PSH
Lower back surgery
Umbilical hernia

Meds: Lasix 40 mg daily, Ativan 1 mg daily, Nadolol 40 mg daily, Aldactone 25 mg daily FΗ

Father: HTN, CKD

Mother: DM2

SH

Abstinent of EtOH since admission

No Tobacco

# Physical exam

Vitals: 36.2 121/53, 69, BMI 26, 96% RA

**HEENT**: mild scleral icterus

CV: RRR, no murmurs

Pulm: CTA bilaterally

GI: soft, +ascites, no rebound or guarding


MSK: 1+ LE edema


Neuro: A+Ox3, no asterixis

Skin: no hyperpigmentation but mild icterus

Psych: normal mood

#### Initial Labs HD #1





6.2	3.2
3.5	63
31	14

INR 1.9 U<sub>Na</sub> 15

8AM Cortisol  $5.2 \rightarrow 12.8 \rightarrow 18.3$ 

MELD score: 22

Child score: 10, class C

# Post Discharge Day #1 Labs

8AM Cortisol 5.9 mcg/dL, ACTH 29.2 8AM Fr Cortisol 1.07 mcg/dL (RR 0.07-0.93)

TSH 3.07 (RR 0.3-4.0)

FT4 1.08 (RR 0.9-1.7)

Seen in endo clinic 2 weeks after discharge.

Hemodynamically stable, no symptoms of adrenal insufficiency. Not started on steroids.

#### **Clinical Questions**

- Assessment of adrenal insufficiency in cirrhosis?
- Effect of corticosteroid therapy in critically ill patients with cirrhosis?
- Etiology of hyponatremia in cirrhosis?

#### **Total Cortisol in Cirrhosis**

- 90% serum cortisol is bound to albumin (20%) and CBG (70%)
- Reduction in these proteins are associated with a reduction in the bound-cortisol fraction.
- Serum total cortisol could be lower without having a low free biologically active hormone.

## Adrenocortical Dysfcn in Cirrhosis

- Al reportedly found in 40-48% patients with variceal bleeding and 26-64% w/ascites
- Hepatoadrenal syndrome: inadequate glucocorticoid activity w/respect to the severity of illness
  - Glucocorticoid resistance in inflammation
  - Decreased HDL levels → decreased steroidogenesis

## Adrenocortical Dysfcn in Cirrhosis

- 250 mcg Cosyntropin is recommended to diagnose AI in critically ill
- Serum total and plasma free cortisol were used to study 43 clinically stable cirrhotics.
  - Prevalence of Al
    - 39% w/standard criteria (peak total < 18mcg/dL)</li>
    - 47% w/CIRCI criteria (∆ cortisol < 9mcg/dL)</li>
    - 12% w/free cortisol (peak plasma < 1.2mcg/dL)</li>
- Free cortisol index: total cortisol/CBG
- LDSST
- Salivary Cortisol

#### Corticosteroid Use in Cirrhosis + Critical Illness

-0.16(0.29)

24 (62)

6.8 (7.9)

6.7 (7.7)

6.7 (7.8)

9.2 (6.4)

27.2 (12.8)

14 (36)

10 (26)

13 (33)

34 (87)

8 (21)

14 (36)

0.11(0.32)

14 (39)

5.6 (8.9)

8.1 (10.9)

6.4 (10.6)

9.6 (6.0)

43.3 (34.0)

5 (14)

6 (17)

4 (11)

25 (69)

3 (8)

15 (42)

p value

0.19 0.64 0.82

0.005

0.0006

0.05

0.54

0.51

0.92

0.86

0.90

0.03

0.34

0.02

0.06

0.14

0.61

-0.27 (-0.40 to -0.12)\*

1.58 (0.91 to 2.55)

1.2 (-2.7 to 5.1)\*

-1.4 (-5.8 to 2.9)\*

0.2 (-4.0 to 4.5)\*

-0.4 (-5.4 to 4.5)\*

-16.1 (-54.5 to 22.4)\*

2.46 (0.98 to 6.21)

1.54 (0.62 to 3.80)

3.00 (1.08 to 8.36)

1.26 (0.98 to 1.61)

2.46 (0.71 to 8.57)

0.86 (0.49 to 1.52)

Outcome	Hydrocortisone n = 39	Placebo <i>n</i> = 36	Relative risk (95% CI)
Mortality			
28-day mortality, no. (%)	33 (85)	26 (72)	1.17 (0.92 to 1.49)
ICU mortality, no. (%)	24 (62)	24 (67)	0.92 (0.66 to 1.30)
Hospital mortality, no. (%)	34 (87)	32 (89)	0.98 (0.83 to 1.16)
Hemodynamic response	$I \times I \times I$	البلالات	1111
Change in norepinephrine infusion rate (day 2 – day 1),	-0.08 (0.22)	0.09 (0.28)	-0.17 (-0.28 to -0.05)

μg/kg per min, mean (SD)

ug/kg per min, mean (SD)

Vasopressor-free days, mean (SD)

Ventilation-free days, mean (SD)

Gastrointestinal bleeding, no. (%)

ICU-acquired bacteremia, no (%)

Hyperglycemia > 10 mmol/L, no. (%)

Ventilator-associated pneumonia, no. (%)

Shock reversal, no. (%)

Other outcomes

Complications

Shock relapse, no. (%)

Arrhythmia, no. (%)

Change in norepinephrine infusion rate (day 3 – day 1),

Renal replacement therapy-free days, mean (SD)

ICU length of stay for ICU survivors, d, mean (SD)


Hospital length of stay for hospital survivors, d, mean (SD)

# Causes of death in Cirrhosis + Septic Shock

HERE UN	Group 1 (n = 25)	Group 2 (n = 50)	O P
Refractory shock (n)	0	20	.001
Type-1 hepatorenal syndrome (n)	2	3	NS
Liver failure (n)	4	4	NS
Variceal bleeding (n)	0	4	NS
Fungal infection (n)	2	0	NS


Group 1- adrenal function assessed, IV hydrocortisone if AI (17 patients- 68%)


Group 2- no assessment of adrenal function, no IV hydrocortisone



#### Hyponatremia in Cirrhosis

- Prevalence is 21.6% with cut-off of 130 (40% if 135)
- Impaired renal capacity to eliminate free water





# Hyponatremia in Cirrhosis

- Poor prognostic indicator
  - Risk factor for hepatic encephalopathy
  - Can be associated with renal failure
  - Patients generally have to be free water restricted
  - Worse prognosis after transplant

#### **Take Home Points**

- Al is over-estimated in cirrhosis based on total cortisol, more standardization of free cortisol levels is needed in this population
- Effect of steroids in critically ill liver patients is still controversial
- Pathophysiology of hyponatremia in cirrhosis

#### References

- Thevenot T, et al. Assessment of Adrenal Function in Cirrhotic Patients Using Concentration of Serum-Free and Salivary Cortisol. Liver International 2011
- Fede G, et al. Assess of Adrenocortical Reserve in Stable Patients with Cirrhosis. Journal of Hepatology 2011;54:243-250.
- Fede G, et al. Adrenocortical Dysfunction in Liver Disease: A Systematic Review. Hepatology 2012;55(4):1282-1291.
- Arabi YM, et al. Low dose Hydrocortisone in Patients with Cirrhosis and Septic Shock: a RCT. CMAJ 2010;182(8):1971-1977.
- Fernandez J, et al. Adrenal Insufficiency in Patients with Cirrhosis and Septic Shock: Effect of Treatment with Hydrocortisone on Survival. Hepatology 2006;44(5):1288-1295.
- Gines P et al. Hyponatremia in Cirrhosis: Pathogenesis, Clinical Significance and Management. Hepatology 2008;48(3):1002-1010.

